Profile
Sector:
HealthcareIndustry:
Medical Care FacilitiesCountry:
GermanyIPO:
17 September 1996Next earnings report:
20 February 2025Last dividends:
17 May 2024Next dividends:
N/APrice
pre-market | 27 min agoAnalysts recommendations
Institutional Ownership
FMS Latest News
Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Oliver Metzger - ODDO BHF Bank Sezgi Oezener - HSBC Giang Nguyen - Citigroup David Adlington - JPMorgan Marianne Bulot - Bank of America Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the report of the Third Quarter 2024 of Fresenius Medical Care Conference Call. I'm Sandra, the Chorus Call operator.
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous range BAD HOMBURG, Germany , Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience WALTHAM, Mass. , Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers.
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
What type of business is Fresenius Medical Care AG & Co KGaA?
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
What sector is Fresenius Medical Care AG & Co KGaA in?
Fresenius Medical Care AG & Co KGaA is in the Healthcare sector
What industry is Fresenius Medical Care AG & Co KGaA in?
Fresenius Medical Care AG & Co KGaA is in the Medical Care Facilities industry
What country is Fresenius Medical Care AG & Co KGaA from?
Fresenius Medical Care AG & Co KGaA is headquartered in Germany
When did Fresenius Medical Care AG & Co KGaA go public?
Fresenius Medical Care AG & Co KGaA initial public offering (IPO) was on 17 September 1996
What is Fresenius Medical Care AG & Co KGaA website?
https://www.freseniusmedicalcare.com
Is Fresenius Medical Care AG & Co KGaA in the S&P 500?
No, Fresenius Medical Care AG & Co KGaA is not included in the S&P 500 index
Is Fresenius Medical Care AG & Co KGaA in the NASDAQ 100?
No, Fresenius Medical Care AG & Co KGaA is not included in the NASDAQ 100 index
Is Fresenius Medical Care AG & Co KGaA in the Dow Jones?
No, Fresenius Medical Care AG & Co KGaA is not included in the Dow Jones index
When was Fresenius Medical Care AG & Co KGaA the previous earnings report?
No data
When does Fresenius Medical Care AG & Co KGaA earnings report?
The next expected earnings date for Fresenius Medical Care AG & Co KGaA is 20 February 2025